POLIVY is given in combination with a chemotherapy regimen. POLIVY plus bendamustine and a rituximab product (BR) is given on the first day of each treatment cycle. Bendamustine is given by itself on the second day of each cycle. Your doctor may have you take additional medicines ahead of time to prepare you for your infusions.
Typically, you will have 3 weeks before the next treatment cycle is given. However, your doctor will decide how long to wait between each cycle and how many cycles you need. Talk to your doctor about how you will receive POLIVY.
Some people may experience side effects during or after the infusion process. Please see Preparing for Infusion for more information about these reactions. If you have questions about dosing or the infusion process, talk to your doctor.
POLIVY is administered as an intravenous (IV) infusion (directly into the vein) in a clinic or infusion center. Talk to your healthcare team if you experience any side effects during or after the infusion.
90-minute first infusion
Your healthcare team will monitor you for a minimum of 90 minutes following your first dose.
30 minutes for every other infusion if the first dose went well
Your healthcare team will continue to monitor you for 30 minutes after the completion of follow-up doses.
Some therapies have a complicated preparation process, but POLIVY is available when you need it. POLIVY is ordered by your doctor and is usually given in a clinic or infusion center, not in a hospital.
The information contained in this section of the site is intended for US healthcare professionals only. Click "OK" if you are a healthcare professional.
The link you have selected will take you away from this site to one that is not owned or controlled by Genentech, Inc. Genentech, Inc. makes no representation as to the accuracy of the information contained on sites we do not own or control. Genentech does not recommend and does not endorse the content on any third-party websites. Your use of third-party websites is at your own risk and subject to the terms and conditions of use for such sites.